These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 6846025

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Tardive dyskinesia with Tourette-like syndrome.
    Seeman MV, Patel J, Pyke J.
    J Clin Psychiatry; 1981 Sep; 42(9):357-8. PubMed ID: 6944306
    [Abstract] [Full Text] [Related]

  • 24. The effects of dopamine D3 agonists and antagonists in a nonhuman primate model of tardive dyskinesia.
    Malik P, Andersen MB, Peacock L.
    Pharmacol Biochem Behav; 2004 Aug; 78(4):805-10. PubMed ID: 15301939
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis.
    Gunne LM, Häggström JE, Sjöquist B.
    Nature; 2004 Aug; 309(5966):347-9. PubMed ID: 6727989
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. [Oral dyskinesis, facial dystonia].
    Nakamura S, Akiguchi I.
    Nihon Rinsho; 1993 Nov; 51(11):2978-82. PubMed ID: 8277580
    [Abstract] [Full Text] [Related]

  • 29. Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes.
    Bishnoi M, Chopra K, Kulkarni SK.
    Eur J Pharmacol; 2006 Dec 15; 552(1-3):55-66. PubMed ID: 17064683
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Effect of chronic treatment with NNC 756, a new D-1 receptor antagonist, or raclopride, a D-2 receptor antagonist, in drug-naive Cebus monkeys: dystonia, dyskinesia and D-1/D-2 supersensitivity.
    Gerlach J, Hansen L.
    J Psychopharmacol; 1993 Jan 15; 7(4):355-64. PubMed ID: 22290999
    [Abstract] [Full Text] [Related]

  • 34. Pharmacological modification of experimental tardive dyskinesia.
    Bárány S, Gunne LM.
    Acta Pharmacol Toxicol (Copenh); 1979 Aug 15; 45(2):107-11. PubMed ID: 115227
    [Abstract] [Full Text] [Related]

  • 35. Polypharmacy and tardive dyskinesia.
    Chowdhury KL, Jalali RK, Abrol A, Saproo RK, Shah BA, Tramboo R.
    J Assoc Physicians India; 1991 Jun 15; 39(6):501-3. PubMed ID: 1682299
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. [Respiratory disorders caused by tardive dyskinesia in psychogeriatric patients].
    Wils V.
    Tijdschr Gerontol Geriatr; 1992 Jun 15; 23(3):109-13. PubMed ID: 1609447
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Extrapyramidal side effects during chronic combined dopamine D1 and D2 antagonist treatment in Cebus apella monkeys.
    Peacock L, Jensen G, Nicholson K, Gerlach J.
    Eur Arch Psychiatry Clin Neurosci; 1999 Jun 15; 249(5):221-6. PubMed ID: 10591986
    [Abstract] [Full Text] [Related]

  • 40. [Utility of quetiapine in tardive dyskinesia].
    Navarro Pacheco BV, Montejo González AL, Martín Carrasco M.
    Actas Esp Psiquiatr; 2003 Jun 15; 31(6):347-52. PubMed ID: 14639511
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.